dc.contributor.author | Hekman, MCH | |
dc.contributor.author | Rijpkema, M | |
dc.contributor.author | Aarntzen, EA | |
dc.contributor.author | Mulder, SF | |
dc.contributor.author | Langenhuijsen, JF | |
dc.contributor.author | Oosterwijk, E | |
dc.contributor.author | Boerman, OC | |
dc.contributor.author | Oyen, WJG | |
dc.contributor.author | Mulders, PFA | |
dc.date.accessioned | 2018-04-17T08:56:02Z | |
dc.identifier.citation | European Urology | |
dc.identifier.issn | 0302-2838 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1645 | |
dc.description.abstract | Based on the high expression of Carbonic Anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of 89Zr-labeled girentuximab PET/CT imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 days after injection of 89Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with 89Zr-girentuximab was useful to confirm or exclude ccRCC, to evaluate the extent of the disease and to differentiate from other cancers. In this group 89Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that 89Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion. Patient summary: 89Zr-girentuximab PET/CT imaging can be a valuable diagnostic tool to identify ccRCC. | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.title | PET/CT with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-16 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-04-16 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European Urology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.embargo.terms | Not known | |
icr.researchteam | Translational Molecular Imaging | en_US |
dc.contributor.icrauthor | Oyen, Willem | en |